Continuous Glucose Monitoring– tag –
-
Wellness CGMs Under Scrutiny: Long-Term Benefits for Non-Diabetics Lack Robust Clinical Evidence
The European Sting Belgium Overview A recent systematic review in the Journal of Medical Internet Research questions the long-term clinical efficacy of continuous glucose monitors (CGMs) for non-diabetics. While CGMs show promise in prom... -
MIT’s Non-Invasive Raman-Based CGM Achieves Accuracy Comparable to Commercial Devices, Signaling Next-Generation Glucose Monitoring Potential
Morld USA Overview MIT researchers have developed a novel Raman-based non-invasive continuous glucose monitoring (CGM) device that reads glucose through the skin without needles. Initial tests demonstrate accuracy comparable to existing ... -
Medtronic Launches Simplera Sync CGM Sensor in South Korea, Streamlining Glucose Management for MiniMed 780G Users
KBR South Korea Overview Medtronic has launched its Simplera Sync Sensor, a new continuous glucose monitoring (CGM) device, in South Korea for users of the MiniMed 780G automated insulin delivery (AID) system. This all-in-one disposable ... -
Dexcom Expands Beyond Diabetes Sensors to Comprehensive Health Platform with G8 Launch, Stelo Introduction, and FDA TEMPO Program Inclusion
Libre Life USA Overview Dexcom is transforming from a diabetes sensor manufacturer into a broader connected health platform, marked by the announcement of its next-gen G8 CGM, a 15-day wear extension for G7 internationally, and the launc... -
FDA Clears Dexcom’s Stelo Glucose Biosensor System as First OTC Continuous Glucose Monitor for Non-Insulin-Using Children Ages 2+
Weence.com USA Overview On June 12, 2026, the FDA approved Dexcom's Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM) for children aged 2 and older who do not use insulin. This system, wh... -
DexCom Reports Strong Q2 2026 Results with 13% Revenue Growth, 50% Operating Income Surge
Stock Titan USA Overview DexCom announced robust Q2 2026 financial results, with revenue up 13% year-over-year, driven by increased disposable sensor volumes and an expanding customer base. The company also reported a significant 50% ris... -
Dexcom G7 Achieves Industry-Leading Accuracy with MARD 8.2-8.5% in Adults, Clinical Data Confirms
diabetesknow.com USA Overview Newly compiled clinical data for 2026 ranks the Dexcom G7 as the most accurate continuous glucose monitor (CGM), reporting a mean absolute relative difference (MARD) of approximately 8.2–8.5% in adults. This... -
MedWatch Technologies Secures $15 Million in Series A Funding for Non-Invasive Glucose Biosensor and Lifestyle Coaching Platform
Cure USA Overview MedWatch Technologies has secured $15 million in Series A financing to accelerate the development of its non-invasive biosensor for glucose-related insights and an integrated lifestyle coaching platform. This capital in... -
Biolinq’s Needle-Free Autonomous Wearable Biosensor, Shine™, Receives FDA De Novo Classification, Establishing New Device Category
EvoNexus USA Overview Biolinq, an EvoNexus graduate company, announced that its Shine™ device, a needle-free autonomous wearable biosensor, has received FDA De Novo classification. This classification creates a new regulatory category fo... -
Eindhoven University of Technology’s GlucoPilot Project Develops AI-Powered Personal Glucose Coach with Smart Ring and Lifestyle Data Integration
Eindhoven University of Technology Netherlands Overview The 'GlucoPilot' project, involving researchers from Eindhoven University of Technology, is developing an AI-powered personal glucose coach. This system integrates continuous glucos...
